Caldiamide sodium anhydrous | CAS# 131410-50-9 (anhydrous)

MedKoo Cat#: 412235 | Name: Caldiamide sodium anhydrous

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Caldiamide sodium anhydrous is a biochemical

Chemical Structure

Caldiamide sodium anhydrous

CAS#131410-50-9 (anhydrous)

Theoretical Analysis

MedKoo Cat#: 412235

Name: Caldiamide sodium anhydrous

CAS#: 131410-50-9 (anhydrous)

Chemical Formula: C16H26CaN5NaO8

Exact Mass: 479.1305

Molecular Weight:

Elemental Analysis: C, 40.08; H, 5.47; Ca, 8.36; N, 14.61; Na, 4.79; O, 26.69

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

122760-91-2 (salt) 128326-81-8 (free base) 131410-50-9 (anhydrous)

Synonym

Caldiamide sodium anhydrous; CCRIS6697; CCRIS-6697; CCRIS 6697

IUPAC/Chemical Name

calcium sodium 5,8-bis(carboxylatomethyl)-11-(2-(methylamino)-2-oxoethyl)-3-oxo-2,5,8,11-tetraazatridecan-13-oate

InChi Key

YOVKQJBQALQTMU-UHFFFAOYSA-K

InChi Code

InChI=1S/C16H29N5O8.Ca.Na/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);;/q;+2;+1/p-3

SMILES Code

CNC(CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(NC)=O)CC([O-])=O)=O.[Na+].[Ca+2]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 0.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yip WL, Soosainather TC, Dyrstad K, Sande SA. Classification of structurally related commercial contrast media by near infrared spectroscopy. J Pharm Biomed Anal. 2014 Mar;90:148-60. doi: 10.1016/j.jpba.2013.11.033. Epub 2013 Dec 7. PMID: 24374816. 2: Fretellier N, Idée JM, Dencausse A, Karroum O, Guerret S, Poveda N, Jestin G, Factor C, Raynal I, Zamia P, Port M, Corot C. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol. 2011 May;46(5):292-300. doi: 10.1097/RLI.0b013e3182056ccf. PMID: 21263333. 3: Pietsch H, Raschke M, Ellinger-Ziegelbauer H, Jost G, Walter J, Frenzel T, Lenhard D, Hütter J, Sieber MA. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. Invest Radiol. 2011 Jan;46(1):48-56. doi: 10.1097/RLI.0b013e3181efd49a. PMID: 20938346. 4: Fretellier N, Idée JM, Guerret S, Hollenbeck C, Hartmann D, González W, Robic C, Port M, Corot C. Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol. 2011 Feb;46(2):85-93. doi: 10.1097/RLI.0b013e3181f54044. PMID: 20938344. 5: Grant D, Johnsen H, Juelsrud A, Løvhaug D. Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol. 2009 Mar;50(2):156-69. doi: 10.1080/02841850802637808. PMID: 19160079. 6: Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008 Jan;43(1):65-75. doi: 10.1097/RLI.0b013e31815e6277. PMID: 18097279. 7: Okazaki O, Kurata T, Yoshioka N, Hakusui H. Pharmacokinetics and stability of caldiamide sodium in rats. Arzneimittelforschung. 1996 Jan;46(1):79-83. PMID: 8821523. 8: Lai JJ, Jamieson GC. Determination of dysprosium in monkey serum by inductively-coupled plasma atomic emission spectrometry (ICP-AES) after the administration of Sprodiamide Injection, a new contrast medium for magnetic resonance imaging. J Pharm Biomed Anal. 1993 Nov-Dec;11(11-12):1129-34. doi: 10.1016/0731-7085(93)80093-g. PMID: 8123724. 9: Carvlin MJ, Rajan SS, Rosa L, Muraki AS, Francisco J, Rocklage SM. Efficacy of nonionic low-osmolar gadodiamide injection in animals with intracranial mass lesions. J Magn Reson Imaging. 1992 Jan-Feb;2(1):19-24. doi: 10.1002/jmri.1880020104. PMID: 1623277.